miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the 39th Annual J.P. Morgan Healthcare Conference
First-of-its-kind, high-throughput and validated sncRNA interrogation platform that provides highly accurate molecular measure of malignancy for detection, risk classification and monitoring of tumors from a single urine specimen without the need for invasive biopsies
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 39th Annual J.P. Morgan Healthcare Conference. Mr. Salman will introduce miR Scientific's proprietary, highly accurate, award winning sncRNA interrogation platform, highlight its recent FDA breakthrough designation and present miR's commercial launch plans for its non-invasive liquid biopsy urine test. Mr. Salman will also introduce clinical collaboration roadmaps, the company's product pipeline and global growth initiatives.
The presentation is scheduled for Wednesday, January 13th, 2021 and will begin at 3:10pm EDT. A live webcast for conference participants will be available here.
About miR Scientific
miR Scientific, LLC, is a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease. Our team developed the miR Scientific Disease Management Platform®, which is comprised of proprietary, non-invasive and highly accurate liquid biopsy urine tests for the detection, classification and monitoring of urological cancers. The Platform is being utilized to commercialize its award-winning miR Sentinel™ Prostate Test. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada and Puerto Rico.